The phase 2 ChonDRAgon study compared ozekibart to placebo in patients with metastatic or unresectable conventional chondrosarcoma who been diagnosed with radiographic progression.

Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive outcome of the Phase II ChonDRAgon trial (NCT04950075), which found that ...

SAN DIEGO - Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced Thursday that its experimental cancer drug ozekibart achieved its primary endpoint in a late-stage clinical trial for chondrosarcoma, a ...

Blank Park Zoo’s veterinary team brought a box turtle, corn snake, two prehensile skinks, and a Tamar wallaby to Iowa Radiology for medical imaging. Judge rules Tampa’s Walton Academy charter school ...

Tempus AI TEM has developed and deployed a suite of advanced algorithms across radiology, helping physicians deliver more precise and personalized care. Its strategic acquisitions have further ...

Note that some links may require registration or subscription. A 61-year-old man who last week was pulled into an MRI machine in New York after he walked into the room wearing a metal chain around his ...

From the Bone Service of the Department of Surgery, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan-Kettering Cancer Center, and the James Ewing Hospital of the City of New York. We ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min One of the region’s largest ...

(A) CCK8 assays showed the proliferation ability of CHS cells with or without TUG1 knockdown. (B) EDU experiments showed the proliferation ability of CHS cells. (C, D) Transwell experiments showed the ...

Chandigarh: Professor Naveen Kalra of PGIMER's department of radiodiagnosis has been awarded the gold medal for his contribution to interventional radiology at the recent silver jubilee conference of ...

Nemvaleukin alfa is under clinical development by Mural Oncology and currently in Phase II for Chondrosarcoma. According to GlobalData, Phase II drugs for Chondrosarcoma does not have sufficient ...

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience. IMP3, CDK4, MDM2 and β-catenin ...